Impact of multidrug resistance on the management of bacterial infections in cirrhosis

被引:2
|
作者
Terra, Carlos [1 ,2 ,3 ,4 ]
de Mattos, Angelo Zambam [3 ,5 ,6 ]
Chagas, Marcelo Souza [1 ,3 ,7 ]
Torres, Andre [1 ,3 ]
Wiltgen, Denusa [3 ,8 ]
Souza, Barbara Muniz [1 ,3 ]
Perez, Renata Mello [3 ,9 ,10 ]
机构
[1] Univ Estado Rio De Janeiro, Gastroenterol Liver Unit, Blvd 28 Setembro,77-3rd floor Vila Isabel, BR-20551030 Rio De Janeiro, RJ, Brazil
[2] Casa Saude Sao Jose Rede Santa Catarina, Liver Unit, BR-22271080 Rio De Janeiro, RJ, Brazil
[3] ABC Grp, Alliance Brazilian Ctr Cirrhosis Car, BR-20551030 Rio De Janeiro, RJ, Brazil
[4] Fed Hosp Lagoa, Liver Unit, BR-22470050 Rio De Janeiro, RJ, Brazil
[5] Fed Univ Hlth Sci Porto Alegre, Grad Program Med Hepatol, BR-90020090 Porto Alegre, RS, Brazil
[6] Irmandade Santa Casa Misericordia Porto Alegre, Gastroenterol & Hepatol Unit, BR-90020090 Porto Alegre, RS, Brazil
[7] Fed Hosp Lagoa, Internal Med, BR-22470050 Rio De Janeiro, RJ, Brazil
[8] Fed Univ Hlth Sci Porto Alegre, Dept Internal Med, BR-90020090 Porto Alegre, Brazil
[9] Fed Univ Rio Janeiro, Hepatol Div, BR-21941617 Rio De Janeiro, RJ, Brazil
[10] DOr Inst Res & Educ, IDOR, Blvd 28 Setembro,77 3rd Floor Vila Isabel, BR-22281100 Rio De Janeiro, RJ, Brazil
关键词
Cirrhosis; Infection; Multidrug-resistance; Bacterial; Antibiotics; Microbiota; RISK-FACTORS; THERAPY; PERITONITIS; MORTALITY;
D O I
10.12998/wjcc.v11.i3.534
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with cirrhosis have an increased risk of infection and differently from other complications, that over the years are improving in their outcomes, infections in cirrhotic patients are still a major cause of hospitalization and death (up to 50% in-hospital mortality). Infections by multidrug-resistant organisms (MDRO) have become a major challenge in the management of cirrhotic patients with significant prognostic and cost-related impact. About one third of cirrhotic patients with bacterial infections is infected with MDR bacteria and their prevalence has increased in recent years. MDR infections have a worse prognosis compared to infections by non-resistant bacteria because they are associated with lower rate of infection resolution. An adequate management of cirrhotic patients with infections caused by MDR bacteria depends on the knowledge of some epidemiological aspects, such as the type of infection (spontaneous bacterial peritonitis, pneumonia, urinary tract infection and spontaneous bacteremia), bacteriological profile of antibiotic resistance at each health care unit and site of infection acquisition (community acquired, healthcare associated or nosocomial). Furthermore, regional variations in the prevalence of MDR infections determine that the choice of empirical antibiotic therapy must be adapted to the local microbiological epidemiology. Antibiotic treatment is the most effective measure to treat infections caused by MDRO. Therefore, optimizing antibiotic prescribing is critical to effectively treat these infections. Identification of risk factors for multidrug resistance is essential to define the best antibiotic treatment strategy in each case and the choice of an effective empirical antibiotic therapy and its early administration is cardinal to reduce mortality. On the other hand, the supply of new agents to treat these infections is very limited. Thus, specific protocols that include preventive measures must be implemented in order to limit the negative impact of this severe complication in cirrhotic patients.
引用
收藏
页码:534 / 544
页数:11
相关论文
共 50 条
  • [1] Impact of multidrug resistance on the management of bacterial infections in cirrhosis
    Carlos Terra
    ?ngelo Zambam de Mattos
    Marcelo Souza Chagas
    Andre Torres
    Denusa Wiltgen
    Barbara Muniz Souza
    Renata Mello Perez
    World Journal of Clinical Cases, 2023, (03) : 534 - 544
  • [2] Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections
    Marciano, Sebastian
    Gutierrez-Acevedo, Maria N.
    Barbero, Sabrina
    del C. Notari, Lorena
    Agozino, Marina
    Fernandez, Jose L.
    Anders, Maria M.
    Grigera, Nadia
    Antinucci, Florencia
    Ganem, Orlando Orozco F.
    Murga, Maria D.
    Perez, Daniela
    Palazzo, Ana
    Rejtman, Liria Martinez
    Duarte, Ivonne G.
    Vorobioff, Julio
    Trevizan, Victoria
    Bulaty, Sofia
    Bessone, Fernando
    Valverde, Marcelo
    Elizondo, Martin
    Bosia, Jose D.
    Borzi, Silvia M.
    Stieben, Teodoro E.
    Masola, Adriano
    Ferretti, Sebastian E.
    Arufe, Diego
    Demirdjian, Ezequiel
    Raffa, Maria P.
    Peralta, Mirta
    Fainboim, Hugo A.
    Vazquez, Cintia E.
    Ruiz, Pablo
    Martinez, Jose E.
    Heffner, Leandro A.
    Odzak, Andrea
    Dirchwolf, Melisa
    Smud, Astrid
    Mendizabal, Manuel
    Bellizzi, Carla
    Martinez, Ana
    Tomatis, Jesica
    Bruno, Andres
    Ramos, Agnel
    Pages, Josefina
    Tevez, Silvina
    Gadano, Adrian C.
    Giunta, Diego H.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (04) : 481 - 491
  • [3] Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections
    Sebastián Marciano
    Maria N. Gutierrez-Acevedo
    Sabrina Barbero
    Lorena del C. Notari
    Marina Agozino
    Jose L. Fernandez
    Maria M. Anders
    Nadia Grigera
    Florencia Antinucci
    Orlando F. Orozco Ganem
    Maria D. Murga
    Daniela Perez
    Ana Palazzo
    Liria Martinez Rejtman
    Ivonne G. Duarte
    Julio Vorobioff
    Victoria Trevizan
    Sofía Bulaty
    Fernando Bessone
    Marcelo Valverde
    Martín Elizondo
    José D. Bosia
    Silvia M. Borzi
    Teodoro E. Stieben
    Adriano Masola
    Sebastian E. Ferretti
    Diego Arufe
    Ezequiel Demirdjian
    Maria P. Raffa
    Mirta Peralta
    Hugo A. Fainboim
    Cintia E. Vazquez
    Pablo Ruiz
    José E. Martínez
    Leandro A. Heffner
    Andrea Odzak
    Melisa Dirchwolf
    Astrid Smud
    Manuel Mendizabal
    Carla Bellizzi
    Ana Martinez
    Jesica Tomatis
    Andres Bruno
    Agñel Ramos
    Josefina Pages
    Silvina Tevez
    Adrian C. Gadano
    Diego H. Giunta
    European Journal of Clinical Microbiology & Infectious Diseases, 2023, 42 : 481 - 491
  • [4] Clinical impact of multidrug-resistant bacterial infections in patients with cirrhosis
    Trad, Nouha
    Mohamed, Ghanem
    Bizid, Sondes
    Abdallah, Hatem Ben
    Bouali, Riadh
    Abdelli, Mohamed Nabil
    FUTURE SCIENCE OA, 2024, 10 (01):
  • [5] Bacterial Infections After Burn Injuries: Impact of Multidrug Resistance
    Lachiewicz, Anne M.
    Hauck, Christopher G.
    Weber, David J.
    Cairns, Bruce A.
    van Duin, David
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (12) : 2130 - 2136
  • [6] Management of bacterial infections in cirrhosis
    Fernandez, Javier
    Gustot, Thierry
    JOURNAL OF HEPATOLOGY, 2012, 56 : S1 - S12
  • [7] Management of Multidrug-Resistant Infections in Cirrhosis
    Gallaher, Charles E.
    Shawcross, Debbie L.
    SEMINARS IN LIVER DISEASE, 2022, 42 (02) : 173 - 187
  • [8] Prevention and Management of Bacterial Infections in Cirrhosis
    Taneja, Sunil K.
    Dhiman, Radha K.
    INTERNATIONAL JOURNAL OF HEPATOLOGY, 2011, 2011
  • [9] Impact of multidrug resistance on outcomes in hematologic cancer patients with bacterial bloodstream infections
    Park, Ki-Ho
    Jung, Ye Ji
    Lee, Hyun Jung
    Kim, Hong Jun
    Maeng, Chi Hoon
    Baek, Sun Kyung
    Han, Jae Joon
    Jeon, Woojae
    Kim, Dong Youn
    Lee, Yu-Mi
    Lee, Mi Suk
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [10] The impact of rifaximin in the prevention of bacterial infections in cirrhosis
    Mariani, M.
    Zuccaro, V.
    Patruno, S. F. A.
    Scudeller, L.
    Sacchi, P.
    Lombardi, A.
    Vecchia, M.
    Columpsi, P.
    Marone, P.
    Filice, G.
    Bruno, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (05) : 1151 - 1158